Beximco Pharma has won the prestigious Global Generics & Biosimilars Awards 2022 in the category of ‘Acquisition of the Year'. Mr Rabbur Reza, COO of the company, received the award in a grand ceremony held in Frankfurt, Germany on November 2, 2022.
Beximco Pharma’s branded generic version of molnupiravir will be marketed as Emorivir. Availability of generic molnupiravir will help broaden access and affordability of COVID-19 treatment, especially in low and middle income countries where access to vaccines has been limited.
We are pleased to inform you that another little piece of history was made on 30 September 2021 in the Bangladesh Pharma Industry - Beximco Pharma has successfully completed the acquisition of 54.6% stake in Sanofi Bangladesh Ltd.